NCT05314764View on ClinicalTrials.gov

Cefiderocol Pharmacokinetics in Adult Patients With Cystic Fibrosis

PHASE4CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

June 1, 2022

Primary Completion Date

June 1, 2024

Study Completion Date

December 11, 2024

Conditions
Cystic FibrosisPneumonia, Bacterial
Interventions
DRUG

Cefiderocol

Patients will receive intravenous cefiderocol every 6 to 8 hours for 4 to 6 doses.

Trial Locations (4)

15213

UPMC Presbyterian Hospital, Pittsburgh

46202

IU Health University Hospital, Indianapolis

75390

UT Southwestern Clements University Hospital, Dallas

06106

Hartford Hospital, Hartford

All Listed Sponsors
collaborator

Shionogi Inc.

INDUSTRY

collaborator

Keystone Bioanalytical, Inc.

UNKNOWN

collaborator

Indiana University Health Methodist Hospital

OTHER

collaborator

University of Pittsburgh Medical Center

OTHER

collaborator

University of Texas

OTHER

lead

Hartford Hospital

OTHER